VEGFR2-targeted therapy not only inhibited angiogenesis but also suppressed CSCs and activated tumor immunity, and thus it might be effective in AFP-positive advanced HCC after Atezolizumab/Bevacizumab. Here, AFP is linked to hepatocellular carcinoma.